A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLC
Status:
Recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
This is a phase II study. All patients are stage IIIB/C or IV non-small cell lung
cancer(NSCLC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1. The purpose
of this study is to evaluate the efficacy and safety of AK112 in combination with
chemotherapy in patients with NSCLC.